{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:34:45Z","timestamp":1794044085787,"version":"4.8.0"},"reference-count":193,"publisher":"European Respiratory Society (ERS)","issue":"174","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2024,7,31]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>The prognosis of people with cystic fibrosis (pwCF) has improved dramatically with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators (CFTRm). The ageing of the cystic fibrosis (CF) population is changing the disease landscape with the emergence of different needs and increasing comorbidities related to both age and long-term exposure to multiple treatments including CFTRm. Although the number of pwCF eligible for this treatment is expected to increase, major disparities in care and outcomes still exist in this population. Moreover, the long-term impact of the use of CFTRm is still partly unknown due to the current short follow-up and experience with their use, thus generating some uncertainties. The future spread and initiation of these drugs at an earlier stage of the disease is expected to reduce the systemic burden of systemic inflammation and its consequences on health. However, the prolonged life expectancy is accompanied by an increasing burden of age-related comorbidities, especially in the context of chronic disease. The clinical manifestations of the comorbidities directly or indirectly associated with CFTR dysfunction are changing, along with the disease dynamics and outcomes. Current protocols used to monitor slow disease progression will need continuous updates, including the composition of the multidisciplinary team for CF care, with a greater focus on the needs of the adult population.<\/jats:p>","DOI":"10.1183\/16000617.0071-2024","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T06:00:45Z","timestamp":1730268045000},"page":"240071","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["The ageing of people living with cystic fibrosis: what to expect now?"],"prefix":"10.1183","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2314-0818","authenticated-orcid":false,"given":"Almudena","family":"Felipe Montiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio \u00c1lvarez","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Culebras","family":"Amigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Traversi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-4993","authenticated-orcid":false,"given":"David","family":"Clofent Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina Loor","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"2024122400074266000_33.174.240071.1","unstructured":"Welsh MJ , Ramsey BW , Accurso F , et al. Cystic fibrosis. In: Valle DL , Antonarakis S , Ballabio A , et al. , eds. The Online Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill Education, 2019."},{"key":"2024122400074266000_33.174.240071.2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1938.01980140114013"},{"key":"2024122400074266000_33.174.240071.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201009-1478CI"},{"key":"2024122400074266000_33.174.240071.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"2024122400074266000_33.174.240071.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409547"},{"key":"2024122400074266000_33.174.240071.6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6\u201311\u2005years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024122400074266000_33.174.240071.7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/17476348.2019.1602040","article-title":"Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis","volume":"13","author":"Cheng","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"2024122400074266000_33.174.240071.8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis","volume":"4","author":"Elborn","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024122400074266000_33.174.240071.9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2213-2600(20)30517-8","article-title":"Long-term safety and efficacy of lumacaftor\u2013ivacaftor therapy in children aged 6\u201311\u2005years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study","volume":"9","author":"Chilvers","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024122400074266000_33.174.240071.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709846"},{"key":"2024122400074266000_33.174.240071.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709847"},{"key":"2024122400074266000_33.174.240071.12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1807120"},{"key":"2024122400074266000_33.174.240071.13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2020.07.023","article-title":"A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11\u2005years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation","volume":"20","author":"Davies","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jcf.2022.02.003","article-title":"A phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor\/ivacaftor in children \u22656\u2005years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant","volume":"21","author":"Sawicki","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/17843286.2022.2145684","article-title":"Real-world data on the efficacy and safety of tezacaftor\u2013ivacaftor in adults living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation","volume":"78","author":"Vincken","year":"2023","journal-title":"Acta Clin Belg"},{"key":"2024122400074266000_33.174.240071.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2024122400074266000_33.174.240071.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2024122400074266000_33.174.240071.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202008-3176LE"},{"key":"2024122400074266000_33.174.240071.19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024122400074266000_33.174.240071.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1986OC"},{"key":"2024122400074266000_33.174.240071.21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.arbres.2023.05.017","article-title":"Experience with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced disease","volume":"59","author":"Carrasco Hern\u00e1ndez","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"2024122400074266000_33.174.240071.22","doi-asserted-by":"crossref","first-page":"1158207","DOI":"10.3389\/fphar.2023.1158207","article-title":"Post-approval studies with the CFTR modulators elexacaftor\u2013tezacaftor\u2013ivacaftor","volume":"14","author":"T\u00fcmmler","year":"2023","journal-title":"Front Pharmacol"},{"key":"2024122400074266000_33.174.240071.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.02.004"},{"key":"2024122400074266000_33.174.240071.24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/17476348.2024.2311109","article-title":"The ageing of cystic fibrosis patients with new modulators: current gaps and challenges","volume":"17","author":"Felipe Montiel","year":"2024","journal-title":"Expert Rev Respir Med"},{"key":"2024122400074266000_33.174.240071.25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01241-2023"},{"key":"2024122400074266000_33.174.240071.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106878"},{"key":"2024122400074266000_33.174.240071.27","unstructured":"Zolin A , Adamoli A , Bakkeheim E, et al. ECFSPR 2022 Annual Data Report. Date last updated: 2024. Date last accessed: 14 July 2024. www.ecfs.eu\/projects\/ecfs-patient-registry\/annual-reports"},{"key":"2024122400074266000_33.174.240071.28","doi-asserted-by":"crossref","unstructured":"K\u00fcnzi L , Easter M , Hirsch MJ , et al. Cystic fibrosis lung disease in the aging population. Front Pharmacol 2021; 12: 601438. doi:10.3389\/fphar.2021.601438","DOI":"10.3389\/fphar.2021.601438"},{"key":"2024122400074266000_33.174.240071.29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12931-019-0993-2","article-title":"Is cellular senescence involved in cystic fibrosis?","volume":"20","author":"Bezzerri","year":"2019","journal-title":"Respir Res"},{"key":"2024122400074266000_33.174.240071.30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5172"},{"key":"2024122400074266000_33.174.240071.31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1515\/cclm-2019-0235","article-title":"Telomere length determinants in childhood","volume":"58","author":"Gorenjak","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2024122400074266000_33.174.240071.32","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3390\/jcm10040590","article-title":"Leukocyte telomere length is not reduced in children and adults with cystic fibrosis but associates with clinical characteristics\u2013a cross-sectional study","volume":"10","author":"Glapa-Nowak","year":"2021","journal-title":"J Clin Med"},{"key":"2024122400074266000_33.174.240071.33","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201503-133AW"},{"key":"2024122400074266000_33.174.240071.34","doi-asserted-by":"crossref","unstructured":"Dumas A , Bernard L , Poquet Y , et al. The role of the lung microbiota and the gut\u2013lung axis in respiratory infectious diseases. Cell Microbiol 2018; 20: e12966. doi:10.1111\/cmi.12966","DOI":"10.1111\/cmi.12966"},{"key":"2024122400074266000_33.174.240071.35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcf.2018.11.003","article-title":"The lung and gut microbiome: what has to be taken into consideration for cystic fibrosis?","volume":"18","author":"H\u00e9ry-Arnaud","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.36","doi-asserted-by":"crossref","unstructured":"Lussac-Sorton F , Charpentier \u00c9 , Imbert S , et al. The gut\u2013lung axis in the CFTR modulator era. Front Cell Infect Microbiol 2023; 13: 1271117. doi:10.3389\/fcimb.2023.1271117","DOI":"10.3389\/fcimb.2023.1271117"},{"key":"2024122400074266000_33.174.240071.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1954OC"},{"key":"2024122400074266000_33.174.240071.38","doi-asserted-by":"crossref","first-page":"e54556","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Jarosz-Griffiths","year":"2020","journal-title":"eLife"},{"key":"2024122400074266000_33.174.240071.39","first-page":"15","article-title":"Cystic fibrosis: detecting frailty in an outpatient clinic","volume":"5","author":"Ferguson","year":"2016","journal-title":"Healthy Aging Res"},{"key":"2024122400074266000_33.174.240071.40","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.healun.2022.07.017","article-title":"Frailty predicts outcomes in cystic fibrosis patients listed for lung transplantation","volume":"41","author":"Koutsokera","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"2024122400074266000_33.174.240071.41","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/jcm13020585","article-title":"Cystic fibrosis in adults: a paradigm of frailty syndrome? An observational study","volume":"13","author":"Iacotucci","year":"2024","journal-title":"J Clin Med"},{"key":"2024122400074266000_33.174.240071.42","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00442-2023"},{"key":"2024122400074266000_33.174.240071.43","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001788"},{"key":"2024122400074266000_33.174.240071.44","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.14309\/ajg.0000000000001527","article-title":"Cystic fibrosis transmembrane conductance regulator modulator use is associated with reduced pancreatitis hospitalizations in patients with cystic fibrosis","volume":"116","author":"Ramsey","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2024122400074266000_33.174.240071.45","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.08.016"},{"key":"2024122400074266000_33.174.240071.47","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0654"},{"key":"2024122400074266000_33.174.240071.48","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.2010.s11010"},{"key":"2024122400074266000_33.174.240071.49","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1768"},{"key":"2024122400074266000_33.174.240071.50","doi-asserted-by":"crossref","first-page":"102899","DOI":"10.1016\/j.dsx.2023.102899","article-title":"Advances in cystic fibrosis-related diabetes: current status and future directions","volume":"17","author":"Lurquin","year":"2023","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"2024122400074266000_33.174.240071.51","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"2024122400074266000_33.174.240071.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.11.010"},{"key":"2024122400074266000_33.174.240071.53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jcmgh.2019.04.013","article-title":"Pathophysiology of cystic fibrosis liver disease: a channelopathy leading to alterations in innate immunity and in microbiota","volume":"8","author":"Fiorotto","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2024122400074266000_33.174.240071.54","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","article-title":"Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies","volume":"76","author":"Dana","year":"2022","journal-title":"J Hepatol"},{"key":"2024122400074266000_33.174.240071.55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4254\/wjh.v10.i1.34","article-title":"Risk factors for hepatic steatosis in adults with cystic fibrosis: similarities to non-alcoholic fatty liver disease","volume":"10","author":"Ayoub","year":"2018","journal-title":"World J Hepatol"},{"key":"2024122400074266000_33.174.240071.56","first-page":"54","article-title":"Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance receptor (CFTR) modulators","volume":"50","author":"Eldredge","year":"2024","journal-title":"Paediatr Respir Rev"},{"key":"2024122400074266000_33.174.240071.57","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(11)60129-X"},{"key":"2024122400074266000_33.174.240071.58","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/HEP.0000000000000646","article-title":"Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations","volume":"79","author":"Sellers","year":"2024","journal-title":"Hepatology"},{"key":"2024122400074266000_33.174.240071.59","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000765"},{"key":"2024122400074266000_33.174.240071.60","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jcf.2019.08.017","article-title":"Cystic fibrosis bone disease treatment: current knowledge and future directions","volume":"18","author":"Putman","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jbspin.2011.05.009","article-title":"Bone loss in adults with cystic fibrosis: prevalence, associated factors, and usefulness of biological markers","volume":"79","author":"Legroux-G\u00e9rot","year":"2012","journal-title":"J Bone Spine"},{"key":"2024122400074266000_33.174.240071.62","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.046516"},{"key":"2024122400074266000_33.174.240071.63","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1629"},{"issue":"Suppl. 2","key":"2024122400074266000_33.174.240071.64","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(11)60004-0","article-title":"European cystic fibrosis bone mineralisation guidelines","volume":"10","author":"Sermet-Gaudelus","year":"2011","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.65","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jcf.2016.09.003","article-title":"Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation","volume":"15","author":"Sermet-Gaudelus","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.66","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2019.01.003","article-title":"Clinical manifestations and risk factors of arthropathy in cystic fibrosis","volume":"147","author":"Roehmel","year":"2019","journal-title":"Respir Med"},{"key":"2024122400074266000_33.174.240071.67","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/biom13030425","article-title":"Cystic fibrosis bone disease: the interplay between CFTR dysfunction and chronic inflammation","volume":"13","author":"Fonseca","year":"2023","journal-title":"Biomolecules"},{"key":"2024122400074266000_33.174.240071.68","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jcf.2023.03.007","article-title":"Autoimmunity in people with cystic fibrosis","volume":"22","author":"Chadwick","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.69","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.jcf.2021.05.003","article-title":"Risk factors for cystic fibrosis arthropathy: data from the German cystic fibrosis registry","volume":"20","author":"Grehn","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.70","first-page":"100332","article-title":"The changing landscape of treatment for cystic fibrosis related diabetes","volume":"35","author":"Amini","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"2024122400074266000_33.174.240071.71","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(88)90063-7"},{"key":"2024122400074266000_33.174.240071.72","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: a CF foundation position paper","volume":"22","author":"Leonard","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.09.002"},{"key":"2024122400074266000_33.174.240071.74","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/phar.2903","article-title":"Real world study on elexacaftor\u2013tezacaftor\u2013ivacaftor impact on cholesterol levels in adults with cystic fibrosis","volume":"44","author":"Lonabaugh","year":"2024","journal-title":"Pharmacotherapy"},{"key":"2024122400074266000_33.174.240071.75","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcf.2022.04.010","article-title":"Onset of systemic arterial hypertension after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis: a case series","volume":"21","author":"Gramegna","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.76","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcf.2021.04.016","article-title":"Cardiovascular complications in cystic fibrosis: a review of the literature","volume":"21","author":"Poore","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.77","first-page":"100308","article-title":"Coronary artery disease in patients with cystic fibrosis \u2013 a case series and review of the literature","volume":"30","author":"Sandouk","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"2024122400074266000_33.174.240071.78","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.088757"},{"key":"2024122400074266000_33.174.240071.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.03.005"},{"key":"2024122400074266000_33.174.240071.80","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0932OC"},{"key":"2024122400074266000_33.174.240071.81","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00750209"},{"key":"2024122400074266000_33.174.240071.82","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.jrn.2017.05.006","article-title":"Cystic fibrosis: a risk condition for renal disease","volume":"27","author":"Santoro","year":"2017","journal-title":"J Ren Nutr"},{"key":"2024122400074266000_33.174.240071.83","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ccm.2014.06.005","article-title":"Cystic fibrosis and sleep","volume":"35","author":"Katz","year":"2014","journal-title":"Clin Chest Med"},{"key":"2024122400074266000_33.174.240071.84","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s12890-022-02243-0","article-title":"Obstructive sleep apnea and nocturnal hypoxemia in adult patients with cystic fibrosis","volume":"22","author":"Welsner","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2024122400074266000_33.174.240071.85","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/ppul.25028","article-title":"Sleep-disordered breathing in cystic fibrosis","volume":"56","author":"Jagpal","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2024122400074266000_33.174.240071.86","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207488"},{"key":"2024122400074266000_33.174.240071.87","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jcf.2018.02.005","article-title":"Implementing the International Committee on Mental Health in Cystic Fibrosis (ICMH) guidelines: screening accuracy and referral-treatment pathways","volume":"17","author":"Verkleij","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.88","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jcf.2023.01.015","article-title":"Suicide attempts in adolescents with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"22","author":"Arslan","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.89","doi-asserted-by":"crossref","first-page":"1156621","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: a case series","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Front Pharmacol"},{"key":"2024122400074266000_33.174.240071.90","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment and depression-related events","volume":"209","author":"Ramsey","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2024122400074266000_33.174.240071.91","first-page":"100280","article-title":"Eating disorders and body image in cystic fibrosis","volume":"26","author":"Darukhanavala","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"2024122400074266000_33.174.240071.92","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ccm.2022.06.014","article-title":"Management of mental health in cystic fibrosis","volume":"43","author":"Bathgate","year":"2022","journal-title":"Clin Chest Med"},{"key":"2024122400074266000_33.174.240071.93","first-page":"915","article-title":"Eating disorders and disordered eating behaviors in cystic fibrosis: a neglected issue","volume":"9","author":"Petropoulou","year":"2022","journal-title":"Children (Basel)"},{"key":"2024122400074266000_33.174.240071.94","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12967-021-03092-x","article-title":"Regional brain tissue changes in patients with cystic fibrosis","volume":"19","author":"Roy","year":"2021","journal-title":"J Transl Med"},{"key":"2024122400074266000_33.174.240071.95","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.chest.2021.09.003","article-title":"Cancer in cystic fibrosis: a narrative review of prevalence, risk factors, screening, and treatment challenges: adult cystic fibrosis series","volume":"161","author":"Maisonneuve","year":"2022","journal-title":"Chest"},{"key":"2024122400074266000_33.174.240071.96","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.483"},{"key":"2024122400074266000_33.174.240071.97","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.2147\/CMAR.S248539","article-title":"CFTR functions as a tumor suppressor and is regulated by DNA methylation in colorectal cancer","volume":"12","author":"Liu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"2024122400074266000_33.174.240071.98","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.251"},{"key":"2024122400074266000_33.174.240071.99","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jcf.2007.07.011","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) gene 5\u2005T allele may protect against prostate cancer: a case\u2013control study in Chinese Han population","volume":"7","author":"Qiao","year":"2008","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.100","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.3892\/or.2015.3829","article-title":"High level of CFTR expression is associated with tumor aggression and knockdown of CFTR suppresses proliferation of ovarian cancer in vitro and in vivo","volume":"33","author":"Xu","year":"2015","journal-title":"Oncol Rep"},{"key":"2024122400074266000_33.174.240071.101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.02.015"},{"key":"2024122400074266000_33.174.240071.102","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2016.07.011","article-title":"Cancer risk among lung transplant recipients with cystic fibrosis","volume":"16","author":"Fink","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.103","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.12.012"},{"key":"2024122400074266000_33.174.240071.104","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/j.chest.2022.01.055","article-title":"Cancer in cystic fibrosis: do not neglect gynecologic cancers","volume":"161","author":"Appelt","year":"2022","journal-title":"Chest"},{"key":"2024122400074266000_33.174.240071.105","doi-asserted-by":"crossref","first-page":"1043691","DOI":"10.3389\/fpubh.2022.1043691","article-title":"Cancer incidence and prevalence in cystic fibrosis patients with and without a lung transplant in France","volume":"10","author":"Rousset-Jablonski","year":"2022","journal-title":"Front Public Health"},{"key":"2024122400074266000_33.174.240071.106","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2147\/PPA.S211769","article-title":"Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data","volume":"13","author":"Rouz\u00e9","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"2024122400074266000_33.174.240071.107","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cger.2022.05.004","article-title":"Polypharmacy in older adults","volume":"38","author":"Canio","year":"2022","journal-title":"Clin Geriatr Med"},{"key":"2024122400074266000_33.174.240071.108","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10354-021-00903-0","article-title":"Polypharmacy in elderly people","volume":"172","author":"Dovjak","year":"2022","journal-title":"Wien Med Wochenschr"},{"key":"2024122400074266000_33.174.240071.109","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024122400074266000_33.174.240071.110","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S1569-1993(23)00467-8","article-title":"P092 Preliminary observations of treatment and symptom reporting in the Home-Reported Outcomes in cystic fibrosis study (HERO-2)","volume":"22","author":"Brown","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.111","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.112","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.113","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2016.03.004"},{"key":"2024122400074266000_33.174.240071.114","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.115","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30171-1"},{"key":"2024122400074266000_33.174.240071.116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.01.006"},{"key":"2024122400074266000_33.174.240071.117","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2023.05.003","article-title":"Eradication of nontuberculous mycobacteria in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor: a multicenter cohort study","volume":"23","author":"Wiesel","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.118","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/mrm.28947","article-title":"Defect distribution index: a novel metric for functional lung MRI in cystic fibrosis","volume":"86","author":"Valk","year":"2021","journal-title":"Magn Reson Med"},{"key":"2024122400074266000_33.174.240071.119","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.202102-0278OC","article-title":"Magnetic resonance imaging detects progression of lung disease and impact of newborn screening in preschool children with cystic fibrosis","volume":"204","author":"Stahl","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024122400074266000_33.174.240071.120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00408-020-00412-8","article-title":"Abnormal lung clearance index in cystic fibrosis children with normal FEV1 and single-breath nitrogen washout test","volume":"199","author":"Kasi","year":"2021","journal-title":"Lung"},{"key":"2024122400074266000_33.174.240071.121","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12890-022-01903-5","article-title":"Lung clearance index to characterize clinical phenotypes of children and adolescents with cystic fibrosis","volume":"22","author":"Gambazza","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2024122400074266000_33.174.240071.122","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/ppul.26938","article-title":"Lung clearance index (LCI2.5) changes after initiation of elexacaftor\/tezacaftor\/ivacaftor in children with cystic fibrosis aged between 6 and 11 years: the \u201creal-world\u201d differs from trial data","volume":"59","author":"Urquhart","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2024122400074266000_33.174.240071.123","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(05)80016-5"},{"issue":"Suppl. 1","key":"2024122400074266000_33.174.240071.124","first-page":"S113","article-title":"Looking toward the future: approaching care of the aging CF patient","volume":"57","author":"Sala","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"2024122400074266000_33.174.240071.125","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/MCP.0000000000001009","article-title":"The modern landscape of fertility, pregnancy, and parenthood in people with cystic fibrosis","volume":"29","author":"Jain","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"2024122400074266000_33.174.240071.126","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.chest.2021.07.024","article-title":"Fertility and pregnancy in cystic fibrosis","volume":"160","author":"Shteinberg","year":"2021","journal-title":"Chest"},{"key":"2024122400074266000_33.174.240071.127","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.clinthera.2023.01.016","article-title":"The impact of highly effective cystic fibrosis transmembrane conductance regulator modulators on the health of female subjects with cystic fibrosis","volume":"45","author":"Taylor-Cousar","year":"2023","journal-title":"Clin Ther"},{"key":"2024122400074266000_33.174.240071.128","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/ppul.26706","article-title":"Use of CFTR modulators in special populations, part 1: pregnancy and lactation","volume":"58","author":"Elijah","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2024122400074266000_33.174.240071.129","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking elexacaftor, tezacaftor, and ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.130","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor\u2013tezacaftor\u2013ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.131","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001289"},{"key":"2024122400074266000_33.174.240071.132","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.133","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor\u2013tezacaftor\u2013ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.134","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.135","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.7326\/L23-0112","article-title":"Treatment of fetal cystic fibrosis with cystic fibrosis transmembrane conductance regulator modulation therapy","volume":"176","author":"Blumenfeld","year":"2023","journal-title":"Ann Intern Med"},{"key":"2024122400074266000_33.174.240071.136","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1055\/s-0042-1759881","article-title":"Diagnosing cystic fibrosis in adults","volume":"44","author":"Barry","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2024122400074266000_33.174.240071.137","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01662"},{"key":"2024122400074266000_33.174.240071.138","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/21556660.2021.1912352","article-title":"Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database","volume":"10","author":"Mehta","year":"2021","journal-title":"J Drug Assess"},{"key":"2024122400074266000_33.174.240071.139","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.08.001"},{"key":"2024122400074266000_33.174.240071.140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1513\/AnnalsATS.202009-1190ED","article-title":"Age at lung transplant impacts post-transplant survival in cystic fibrosis; why?","volume":"18","author":"Clausen","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2024122400074266000_33.174.240071.141","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chest.2022.07.004","article-title":"The changing epidemiology of cystic fibrosis: the implications for adult care","volume":"163","author":"Burgel","year":"2023","journal-title":"Chest"},{"key":"2024122400074266000_33.174.240071.142","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/life13071600","article-title":"Lung transplantation in a new era in the field of cystic fibrosis","volume":"13","author":"Huang","year":"2023","journal-title":"Life"},{"key":"2024122400074266000_33.174.240071.143","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jcf.2023.02.011","article-title":"Position paper: models of post-transplant care for individuals with cystic fibrosis","volume":"22","author":"McKone","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.144","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.healun.2021.04.011","article-title":"Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients","volume":"40","author":"Shah","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2024122400074266000_33.174.240071.145","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2014.06.014"},{"key":"2024122400074266000_33.174.240071.146","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.07.005"},{"key":"2024122400074266000_33.174.240071.147","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.03.002","article-title":"Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines","volume":"18","author":"Ramos","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.148","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14232"},{"key":"2024122400074266000_33.174.240071.149","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ccr3.2053","article-title":"Lumacaftor\/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azoles","volume":"7","author":"Chouchane","year":"2019","journal-title":"Clin Case Rep"},{"key":"2024122400074266000_33.174.240071.150","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.healun.2021.08.009","article-title":"CFTR modulator use in post lung transplant recipients","volume":"40","author":"Benninger","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2024122400074266000_33.174.240071.151","doi-asserted-by":"crossref","unstructured":"Hayes D , Darland LK , Hjelm MA , et al. To treat or not to treat: CFTR modulators after lung transplantation. Pediatr Transplant 2021; 25: e14007. doi:10.1111\/petr.14007","DOI":"10.1111\/petr.14007"},{"key":"2024122400074266000_33.174.240071.152","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jcf.2021.07.017","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor in liver transplant patients with cystic fibrosis","volume":"21","author":"McKinzie","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.153","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ppul.25779","article-title":"The use of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis postliver transplant: a case series","volume":"57","author":"Ragan","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"2024122400074266000_33.174.240071.154","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/phar.2710","article-title":"Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients","volume":"42","author":"Doligalski","year":"2022","journal-title":"Pharmacotherapy"},{"key":"2024122400074266000_33.174.240071.155","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ppul.26217","article-title":"Outcome of elexacaftor\/tezacaftor\/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation","volume":"58","author":"\u00d8rum","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2024122400074266000_33.174.240071.156","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.157","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1002\/ppul.26396","article-title":"Use of CFTR modulators in special populations, part 3: Solid organ transplant","volume":"58","author":"Kadouh","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2024122400074266000_33.174.240071.158","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.jcf.2021.05.008","article-title":"Ivacaftor\u2013elexacaftor\u2013tezacaftor and tacrolimus combination in cystic fibrosis","volume":"21","author":"Smith","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.159","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jcf.2023.09.017","article-title":"Patient perspectives on elexacaftor\/tezacaftor\/ivacaftor after lung transplant","volume":"23","author":"Young","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.160","first-page":"6","article-title":"CFTR modulator therapy in patients with cystic fibrosis and an organ transplant","volume":"27","author":"Mitchell","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"2024122400074266000_33.174.240071.161","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s41030-021-00170-9","article-title":"CFTR modulator therapy and its impact on lung transplantation in cystic fibrosis","volume":"7","author":"Benden","year":"2021","journal-title":"Pulm Ther"},{"key":"2024122400074266000_33.174.240071.162","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"DiMango","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.163","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.01.007"},{"key":"2024122400074266000_33.174.240071.164","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1002\/ppul.26698","article-title":"Use of CFTR modulators in special populations, part 2: severe lung disease","volume":"58","author":"Elijah","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2024122400074266000_33.174.240071.165","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202011-4153OC"},{"key":"2024122400074266000_33.174.240071.166","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jcf.2021.05.009","article-title":"Short-term effect of elexacaftor\u2013tezacaftor\u2013ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease","volume":"20","author":"Bermingham","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.167","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01959-2023"},{"key":"2024122400074266000_33.174.240071.168","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S2213-2600(23)00324-7","article-title":"Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy","volume":"11","author":"Hisert","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024122400074266000_33.174.240071.169","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcf.2022.04.007","article-title":"Current prices versus minimum costs of production for CFTR modulators","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.170","doi-asserted-by":"crossref","first-page":"1163391","DOI":"10.3389\/fphar.2023.1163391","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap!","volume":"14","author":"Zampoli","year":"2023","journal-title":"Front Pharmacol"},{"key":"2024122400074266000_33.174.240071.171","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor\u2013tezacaftor\u2013deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024122400074266000_33.174.240071.172","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/antibiotics10050486","article-title":"Treatment of pulmonary disease of cystic fibrosis: a comprehensive review","volume":"10","author":"Moreno","year":"2021","journal-title":"Antibiotics"},{"key":"2024122400074266000_33.174.240071.173","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/jor2020005","article-title":"CFTR modulator therapy for rare CFTR mutants","volume":"2","author":"Mergiotti","year":"2022","journal-title":"J Respir"},{"key":"2024122400074266000_33.174.240071.174","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.jcf.2017.09.005","article-title":"Recent progress in translational cystic fibrosis research using precision medicine strategies","volume":"17","author":"Cholon","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.175","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/jpm12081321","article-title":"Advances in preclinical in vitro models for the translation of precision medicine for cystic fibrosis","volume":"12","author":"Silva","year":"2022","journal-title":"J Pers Med"},{"key":"2024122400074266000_33.174.240071.176","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000521"},{"key":"2024122400074266000_33.174.240071.177","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.05.004"},{"key":"2024122400074266000_33.174.240071.178","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02379-2018"},{"key":"2024122400074266000_33.174.240071.179","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad8278"},{"key":"2024122400074266000_33.174.240071.180","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.3390\/ijms22094448","article-title":"Nasal epithelial cell-based models for individualized study in cystic fibrosis","volume":"22","author":"Keegan","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024122400074266000_33.174.240071.181","doi-asserted-by":"crossref","first-page":"10358","DOI":"10.3390\/ijms241210358","article-title":"Theratyping of the rare CFTR genotype A559\u2005T in rectal organoids and nasal cells reveals a relevant response to elexacaftor (VX-445) and tezacaftor (VX-661) combination","volume":"24","author":"Kleinfelder","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024122400074266000_33.174.240071.182","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00110-2023"},{"key":"2024122400074266000_33.174.240071.183","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1186\/s13063-022-07047-5","article-title":"Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b\/2, multicenter, randomized, double-blind, placebo-controlled trial","volume":"23","author":"Tamma","year":"2022","journal-title":"Trials"},{"key":"2024122400074266000_33.174.240071.184","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac453"},{"key":"2024122400074266000_33.174.240071.185","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jcf.2017.06.012","article-title":"The potential of phage therapy in cystic fibrosis: essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways","volume":"16","author":"Trend","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.186","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ccm.2022.06.008","article-title":"Novel approaches to multidrug-resistant infections in cystic fibrosis","volume":"43","author":"Murray","year":"2022","journal-title":"Clin Chest Med"},{"key":"2024122400074266000_33.174.240071.187","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.3390\/ijms21113903","article-title":"Gene therapy for cystic fibrosis: progress and challenges of genome editing","volume":"21","author":"Maule","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2024122400074266000_33.174.240071.188","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12967-021-03099-4","article-title":"Gene therapy for cystic fibrosis: new tools for precision medicine","volume":"19","author":"Lee","year":"2021","journal-title":"J Transl Med"},{"key":"2024122400074266000_33.174.240071.189","doi-asserted-by":"crossref","first-page":"1015926","DOI":"10.3389\/fphar.2022.1015926","article-title":"Gene therapy for cystic fibrosis: challenges and prospects","volume":"13","author":"Sui","year":"2022","journal-title":"Front Pharmacol"},{"key":"2024122400074266000_33.174.240071.190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jcf.2021.08.011","article-title":"The impact of cystic fibrosis on the working life of patients: a systematic review","volume":"21","author":"Leso","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024122400074266000_33.174.240071.191","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12913-015-1061-3","article-title":"Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom","volume":"15","author":"Angelis","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"2024122400074266000_33.174.240071.192","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10198-016-0781-6","article-title":"Social\/economic costs and health-related quality of life in patients with cystic fibrosis in Europe","volume":"17","author":"Chevreul","year":"2016","journal-title":"Eur J Health Econ"},{"key":"2024122400074266000_33.174.240071.193","first-page":"599","article-title":"Real-world outcomes and direct care cost before and after elexacaftor\/tezacaftor\/ivacaftor initiation in commercially insured members with cystic fibrosis","volume":"29","author":"Marshall","year":"2023","journal-title":"J Manag Care Spec Pharm"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0071-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:07:56Z","timestamp":1740355676000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0071-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":193,"journal-issue":{"issue":"174","published-online":{"date-parts":[[2024,10,30]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1183\/16000617.0071-2024"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0071-2024","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}